vs
Side-by-side financial comparison of Climb Global Solutions, Inc. (CLMB) and Nutex Health, Inc. (NUTX). Click either name above to swap in a different company.
Climb Global Solutions, Inc. is the larger business by last-quarter revenue ($182.4M vs $151.7M, roughly 1.2× Nutex Health, Inc.). Nutex Health, Inc. runs the higher net margin — 7.8% vs 1.8%, a 6.0% gap on every dollar of revenue. On growth, Climb Global Solutions, Inc. posted the faster year-over-year revenue change (32.1% vs -41.1%). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs 40.7%).
Univar Solutions Inc. is a global chemical and ingredients distributor and provider of value-added services.
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
CLMB vs NUTX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $182.4M | $151.7M |
| Net Profit | $3.3M | $11.8M |
| Gross Margin | 14.5% | 30.4% |
| Operating Margin | 2.1% | 20.4% |
| Net Margin | 1.8% | 7.8% |
| Revenue YoY | 32.1% | -41.1% |
| Net Profit YoY | -9.5% | -80.8% |
| EPS (diluted) | $0.18 | $2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $182.4M | — | ||
| Q4 25 | $193.8M | $151.7M | ||
| Q3 25 | $161.3M | $267.8M | ||
| Q2 25 | $159.3M | $244.0M | ||
| Q1 25 | $138.0M | $211.8M | ||
| Q4 24 | $161.8M | $257.6M | ||
| Q3 24 | $119.3M | $78.8M | ||
| Q2 24 | $92.1M | $76.1M |
| Q1 26 | $3.3M | — | ||
| Q4 25 | $7.0M | $11.8M | ||
| Q3 25 | $4.7M | $55.4M | ||
| Q2 25 | $6.0M | $-17.7M | ||
| Q1 25 | $3.7M | $21.2M | ||
| Q4 24 | $7.0M | $61.6M | ||
| Q3 24 | $5.5M | $-8.8M | ||
| Q2 24 | $3.4M | $-364.0K |
| Q1 26 | 14.5% | — | ||
| Q4 25 | 15.4% | 30.4% | ||
| Q3 25 | 15.9% | 57.8% | ||
| Q2 25 | 16.5% | 51.2% | ||
| Q1 25 | 16.9% | 55.9% | ||
| Q4 24 | 19.3% | 55.0% | ||
| Q3 24 | 20.3% | 27.8% | ||
| Q2 24 | 20.2% | 29.7% |
| Q1 26 | 2.1% | — | ||
| Q4 25 | 4.9% | 20.4% | ||
| Q3 25 | 4.3% | 48.7% | ||
| Q2 25 | 5.0% | 13.8% | ||
| Q1 25 | 3.5% | 38.1% | ||
| Q4 24 | 7.2% | 44.4% | ||
| Q3 24 | 7.1% | 12.3% | ||
| Q2 24 | 4.6% | 7.0% |
| Q1 26 | 1.8% | — | ||
| Q4 25 | 3.6% | 7.8% | ||
| Q3 25 | 2.9% | 20.7% | ||
| Q2 25 | 3.7% | -7.3% | ||
| Q1 25 | 2.7% | 10.0% | ||
| Q4 24 | 4.3% | 23.9% | ||
| Q3 24 | 4.6% | -11.2% | ||
| Q2 24 | 3.7% | -0.5% |
| Q1 26 | $0.18 | — | ||
| Q4 25 | $1.51 | $2.34 | ||
| Q3 25 | $1.02 | $7.76 | ||
| Q2 25 | $1.30 | $-2.95 | ||
| Q1 25 | $0.81 | $3.33 | ||
| Q4 24 | $1.52 | $11.56 | ||
| Q3 24 | $1.19 | $-1.72 | ||
| Q2 24 | $0.75 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.8M | $185.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $118.4M | $329.4M |
| Total Assets | $458.8M | $918.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $41.8M | — | ||
| Q4 25 | $36.6M | $185.6M | ||
| Q3 25 | $49.8M | $166.0M | ||
| Q2 25 | $28.6M | $96.7M | ||
| Q1 25 | $32.5M | $84.7M | ||
| Q4 24 | $29.8M | $40.6M | ||
| Q3 24 | $22.1M | $46.9M | ||
| Q2 24 | $48.4M | $40.8M |
| Q1 26 | $118.4M | — | ||
| Q4 25 | $116.6M | $329.4M | ||
| Q3 25 | $109.3M | $317.2M | ||
| Q2 25 | $105.2M | $235.3M | ||
| Q1 25 | $95.6M | $176.9M | ||
| Q4 24 | $90.6M | $132.4M | ||
| Q3 24 | $87.7M | $60.4M | ||
| Q2 24 | $79.8M | $62.7M |
| Q1 26 | $458.8M | — | ||
| Q4 25 | $460.2M | $918.5M | ||
| Q3 25 | $376.1M | $964.5M | ||
| Q2 25 | $420.7M | $841.0M | ||
| Q1 25 | $370.1M | $761.9M | ||
| Q4 24 | $469.2M | $655.3M | ||
| Q3 24 | $371.9M | $438.5M | ||
| Q2 24 | $302.8M | $422.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $70.4M |
| Free Cash FlowOCF − Capex | — | $69.0M |
| FCF MarginFCF / Revenue | — | 45.5% |
| Capex IntensityCapex / Revenue | — | 0.9% |
| Cash ConversionOCF / Net Profit | — | 5.95× |
| TTM Free Cash FlowTrailing 4 quarters | — | $245.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-11.9M | $70.4M | ||
| Q3 25 | $22.2M | $99.5M | ||
| Q2 25 | $-2.2M | $27.3M | ||
| Q1 25 | $8.5M | $51.0M | ||
| Q4 24 | $16.0M | $54.0K | ||
| Q3 24 | $-3.6M | $6.8M | ||
| Q2 24 | $7.3M | $13.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $69.0M | ||
| Q3 25 | — | $99.2M | ||
| Q2 25 | — | $26.5M | ||
| Q1 25 | — | $50.9M | ||
| Q4 24 | — | $-341.0K | ||
| Q3 24 | — | $6.2M | ||
| Q2 24 | — | $12.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 45.5% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | — | 10.9% | ||
| Q1 25 | — | 24.0% | ||
| Q4 24 | — | -0.1% | ||
| Q3 24 | — | 7.8% | ||
| Q2 24 | — | 16.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | — | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | -1.70× | 5.95× | ||
| Q3 25 | 4.73× | 1.80× | ||
| Q2 25 | -0.37× | — | ||
| Q1 25 | 2.30× | 2.40× | ||
| Q4 24 | 2.29× | 0.00× | ||
| Q3 24 | -0.66× | — | ||
| Q2 24 | 2.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLMB
Segment breakdown not available.
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
